Related Experiment Video
Updated: Aug 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Nitric oxide mediates the effect of fluvastatin on intercellular adhesion molecule-1 and platelet endothelial cell
Eleftherios S Xenos1, Scott L Stevens, Michael B Freeman
1Department of Surgery, Division of Vascular Surgery, University of Tennessee Medical Center, Knoxville, TN 37920, USA. exenos@mc.utmck.edu
Insights
Fluvastatin reduces intercellular adhesion molecule-1 (ICAM-1) and platelet endothelial cell adhesion molecule-1 (PECAM-1) expression in endothelial cells. This effect is mediated by nitric oxide and involves increased endothelial nitric oxide synthase (eNOS) activity.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Pharmacology
Background:
- Atherosclerosis pathogenesis involves leukocyte and platelet adhesion to endothelial cells via adhesion molecules.
- Statins are known to decrease the expression of these adhesion molecules.
- The specific pathway by which fluvastatin affects adhesion molecule expression requires further elucidation.
Purpose of the Study:
- To investigate whether fluvastatin decreases intercellular adhesion molecule-1 (ICAM-1) and platelet endothelial cell adhesion molecule-1 (PECAM-1) expression.
- To determine if this decrease is mediated through a nitric oxide pathway.
- To examine the effect of fluvastatin on endothelial nitric oxide synthase (eNOS) and AMP kinase (AMPK) signaling.
Main Methods:
- Human iliac artery endothelial cells (HIAECs) were treated with fluvastatin in the presence or absence of N-monomethyl-L-arginine (L-NMMA), a nitric oxide synthase inhibitor.
- Flow cytometry was used to measure ICAM-1 and PECAM-1 expression.
- Nitrate/nitrite levels in the supernatant and protein levels of eNOS, phosphorylated eNOS, and AMPK were determined via immunoblotting.
Main Results:
- Fluvastatin (10 and 20 microM) significantly reduced basal ICAM-1 and PECAM-1 expression in HIAECs.
- The inhibitory effect of fluvastatin on adhesion molecule expression was abolished by L-NMMA.
- Fluvastatin treatment increased eNOS and AMPK protein content, as well as Ser(1177)-phosphorylated eNOS levels, and elevated nitric oxide production.
Conclusions:
- Fluvastatin decreases the basal expression of ICAM-1 and PECAM-1 in endothelial cells.
- This effect is dependent on nitric oxide production and involves the up-regulation and activation of eNOS.
- Fluvastatin enhances eNOS activity through increased phosphorylation, potentially via AMPK activation.
Abstract:
Leukocyte and platelet adhesion to endothelial cells, an early step in the pathogenesis of atherosclerosis, is mediated through adhesion molecules. It has been shown that statins decrease adhesion molecule expression. We examined the hypothesis that fluvastatin decreased intercellular adhesion molecule-1 (ICAM-1) and platelet endothelial cell adhesion molecule-1 (PECAM-1) expression through a nitric oxide-mediated pathway. Human iliac artery endothelial cells were exposed to fluvastatin in the presence or absence of 2 mM N-monomethyl-L-arginine (L-NMMA). Flow cytometry analysis was used to measure ICAM-1 and PECAM-1 expression. In a separate experiment, confluent cell cultures were exposed in a serum-free medium to fluvastatin 20 microM, and the supernatant was collected for nitrate/nitrite determination after 6 and 48 hr of incubation. Protein was isolated and processed for immunoblotting with monoclonal antibodies specific for endothelial nitric oxide synthase (eNOS), Ser(1177)-phosphorylated eNOS, and AMP kinase. Relative band intensity was assessed with densitometry. Results are presented as the mean +/- standard deviation (SD), and p < 0.05 was considered significant. ICAM-1 and PECAM-1 were expressed constitutively. Human iliac artery endothelial cells (HIAECS) treated with 5 microM fluvastatin did not exhibit reduced expression of PECAM-1 or ICAM-1. Incubation with 10 microM fluvastatin reduced basal expression of both ICAM-1 and PECAM-1. Fluorescence intensity (FI) for these substance was as follows: 3638 +/- 1671, p = 0.01 and PECAM-1 vs. control FI 276 +/- 52 vs. 522 +/- 78, p = 0.02. In the presence of 2 mM L-NMMA, fluvastatin failed to decrease the expression of ICAM-1 (fluvastatin 10 microM + L-NMMA: FI was 3042 +/- 1378 vs. 3638 +/- 1671 for the control p = 0.01) or PECAM-1 (fluvastatin 10 microM + L-NMMA: FI was 415 +/- 188 vs. 522 +/- 78 for the control, p = 0.1). Incubation with 20 microM fluvastatin similarly reduced ICAM-1 expression (FI was 2014 +/- 1595 vs. 3638 +/- 1671 for the control, p = 0.02) and PECAM-1 expression (FI was 196 +/- 109 vs. 522 +/- 78 for the control, p = 0.02). This reduction was prevented in the presence of 2 mM L-NMMA. L-NMMA in a concentration of 2 mM had no significant effect on adhesion molecule expression (p > 0.05 for all comparisons of the control FI versus 2 mM L-NMMA mean FI). After a 48 hr incubation with 20 microM fluvastatin there was a 219 +/- 35% increase in the cell eNOS protein content (p = 0.01) and a 170 +/- 26% increase in the cell AMPK protein content (p = 0.02). Ser(1177)-phosphorylated eNOS protein levels were increased by 41 +/- 8% (p = 0.03). The nitric oxide concentration in the medium of the HIAEC treated with 20 microM fluvastatin for 48 hr was significantly higher than that in the control (p = 0.0004), pointing to increased production during the incubation period. Fluvastatin thus decreases basal expression of ICAM-1 and PECAM-1. Competitive inhibition of eNOS with L-NMMA abolishes the effect of fluvastatin on ICAM-1 and PECAM-1 expression. The statin up-regulates eNOS and AMP kinase, one of the enzymes that activates eNOS via phosphorylation at Ser(1177). We have shown that after a 48-hr exposure to fluvastatin there is an increased amount of the phosphorylated enzyme in the endothelial cells.
Related Concept Videos
Nitric Oxide Signaling Pathway
Intracellular Signaling Affects Focal Adhesions
Some...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Antihypertensive Drugs: Action of Calcium Channel Blockers
Regulation of Angiogenesis and Blood Supply

